Spotlight Therapeutics, a Bay Area biotech company that raised $66 million from investors, including GV, has shut down.

The FDA recently granted EXG-34217 Rare Pediatric Disease Designation (RPDD) and Regenerative Medicine Advanced Therapy (RMAT) Designation.

The global Gene Therapy market, valued at US$7.21 billion in 2023, is forecasted to grow at a robust CAGR of 19.4%, reaching ...

According to a research report "Global Defense Industry Outlook" The global military expenditure is estimated to be USD 2,563.1 billion in ...

It probably should not be too much of a surprise that Stoicism, one of the most deviant and uncharacteristic branches of ...

Q32 Bio Logo (PRNewsfoto/Q32 Bio) "We have conviction that bempikibart is differentiated from existing AA therapies and has the potential to transform the treatment paradigm for this disease. This is ...

An illustration of a magnifying glass. An illustration of a magnifying glass.

Logo (PRNewsfoto/TransCode Therapeutics, Inc.) Several patients ... a microRNA widely believed to be critical to the emergence and progression of many metastatic cancers. TransCode's 2023 Phase ...

knowlesi allows us to understand the molecular strategies that the parasite takes to grow, to respond to environmental ...

Blue Yonder Holding, Inc. (Blue Yonder), the world leader in digital supply chain transformation, today released its Q4 2024 and FY24 company highlights, as well as the industry trends that matter ...